TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Investing.com - Acumen Pharmaceuticals (NASDAQ: ABOS) reported first quarter EPS of $-0.32, $0.05 worse than the analyst estimate of $-0.27. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Acumen Pharmaceuticals's stock price closed at $3.92. It is down -18.50% in the last 3 months and down -15.24% in the last 12 months.
Acumen Pharmaceuticals saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Acumen Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Acumen Pharmaceuticals's Financial Health score is "fair performance".
Check out Acumen Pharmaceuticals's recent earnings performance, and Acumen Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar